Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

0.2 ML ocriplasmin 2.5 MG/ML Injection

Known as: ocriplasmin 0.5 MG in 0.2 ML Injection, OCRIPLASMIN 0.5MG/0.2ML OPH INJ, OCRIPLASMIN 0.5MG/0.2ML INJ,OPH [VA Product] 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Hintergrund Bei der vitreomakularen Traktion (VMT) besteht eine abnormal starke Adharenz zwischen Netzhaut und Glaskorperkortex… Expand
Is this relevant?
2016
2016
Purpose: To assess the stiffness of the human internal limiting membrane (ILM) and evaluate potential changes of mechanical… Expand
  • figure 2
  • figure 3
Is this relevant?
Review
2016
Review
2016
ZusammenfassungHintergrundDie Behandlung einer vitreomakulären Traktion (VMT) mit Ocriplasmin (Jetrea®) war in großen Phase-3… Expand
Is this relevant?
2016
2016
Abstract Objective: The purpose of this study was to evaluate the safety of intravitreal ocriplasmin prospectively, reporting… Expand
Is this relevant?
Review
2015
Review
2015
PURPOSE To report initial experience with intravitreal ocriplasmin (IVO) and to describe outer retina reflectivity changes… Expand
  • table 1
  • table 2
  • figure 1
  • table 4
  • figure 3
Is this relevant?
2015
2015
PurposeTo evaluate prospectively the anatomical and functional results after ocriplasmin injection in patients with vitreomacular… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Vitreomacular traction and vitreomacular traction with macular hole are conditions associated with visual disturbance and… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
IMPORTANCE Ocriplasmin cleaves fibronectin and laminin, components of the vitreous gel, and is used as a pharmacologic treatment… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
IMPORTANCE Clinical trials indicate that visual impairment is significantly greater in patients receiving ocriplasmin than… Expand
  • figure 1
  • figure 2
Is this relevant?